Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets OTCQX - Delayed Quote USD

Roche Holding AG (RHHBF)

Compare
350.00
0.00
(0.00%)
At close: March 28 at 4:00:00 PM EDT
Loading Chart for RHHBF
  • Previous Close 0.00
  • Open 350.00
  • Bid 337.05 x 1800
  • Ask 372.53 x 1000
  • Day's Range 350.00 - 350.00
  • 52 Week Range 243.42 - 380.00
  • Volume 200
  • Avg. Volume 171
  • Market Cap (intraday) 269.665B
  • Beta (5Y Monthly) 0.17
  • PE Ratio (TTM) 30.02
  • EPS (TTM) 11.66
  • Earnings Date Jan 30, 2025
  • Forward Dividend & Yield 10.97 (3.13%)
  • Ex-Dividend Date Mar 27, 2025
  • 1y Target Est --

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.

www.roche.com

103,249

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RHHBF

View More

Performance Overview: RHHBF

Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

RHHBF
16.21%
MSCI WORLD (^990100-USD-STRD)
2.26%

1-Year Return

RHHBF
32.20%
MSCI WORLD (^990100-USD-STRD)
5.75%

3-Year Return

RHHBF
9.61%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

RHHBF
30.56%
MSCI WORLD (^990100-USD-STRD)
98.92%

Compare To: RHHBF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RHHBF

View More

Valuation Measures

Annual
As of 3/28/2025
  • Market Cap

    269.66B

  • Enterprise Value

    291.26B

  • Trailing P/E

    30.02

  • Forward P/E

    14.93

  • PEG Ratio (5yr expected)

    0.75

  • Price/Sales (ttm)

    3.98

  • Price/Book (mrq)

    7.75

  • Enterprise Value/Revenue

    4.12

  • Enterprise Value/EBITDA

    15.45

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.27%

  • Return on Assets (ttm)

    12.75%

  • Return on Equity (ttm)

    26.47%

  • Revenue (ttm)

    62.39B

  • Net Income Avi to Common (ttm)

    8.28B

  • Diluted EPS (ttm)

    11.66

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    17.33B

  • Total Debt/Equity (mrq)

    100.60%

  • Levered Free Cash Flow (ttm)

    13.67B

Research Analysis: RHHBF

View More

Company Insights: RHHBF

Research Reports: RHHBF

View More

People Also Watch